Antibody

29개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved29 programs
AntibodyCurated CoreFDARocheApproved

trastuzumab (Herceptin, Ogivri, Herzuma)

HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2

#HER2#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1100Status Approved
AntibodyCurated CoreFDABeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyCurated CoreFDAJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyCurated CoreFDAAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
AntibodyCurated CorestaleJunshi BiosciencesPhase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 145Status Recruiting
AntibodyLimited DatastalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#Popular#monoclonal-antibody+4
Trials 143Status Recruiting
AntibodyCurated CorestaleEli Lilly and CompanyPhase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 117Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Venous Thrombosis · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 82Status Recruiting
AntibodyLimited DatastaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#monoclonal-antibody#GastricAdenocarcinoma+1
Trials 18Status Active
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, Administration of ceralasertib and durvalumab)

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer · Adv Solid Malig - H&N SCC, ATM Pro / Def

#AdvSolidMalig-HNSCCATMProDef#Antibody#Phase1#monoclonal-antibody#AdvSolidMalig-HNSCC+3
Trials 12Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 1

Andecaliximab (Andecaliximab)

Gastric Adenocarcinoma · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase1#monoclonal-antibody#GastricAdenocarcinoma+1
Trials 3Status Discontinued
AntibodyLimited DatastaleAmgenPhase 2

Bemarituzumab (Bemarituzumab)

Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#monoclonal-antibody#Adenocarcinoma+1
Trials 2Status Active
AntibodyLimited DatastaleMacroGenicsPhase 3

Tebotelimab (Tebotelimab)

Gastric Cancer; Gastroesophageal Junction Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase3#monoclonal-antibody#GastricCancer+2
Trials 2Status Discontinued
AntibodyLimited DatastaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#GastricAdenocarcinoma+1
Trials 2Status Recruiting
AntibodyLimited DatastaleShanghai Zhongshan HospitalPhase 2

nivolumab (Opdivo, Anlotinib Hydrochloride With Nivolumab)

Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#EsophagealSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#MetastaticGastricCancer+1
Trials 1Status Active
AntibodyLimited DatastaleHighlight TherapeuticsPhase 2

pembrolizumab (Keytruda, BO-112 with pembrolizumab)

Colorectal Cancer; Gastric Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#GastricCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleNeovii BiotechPhase 3

Removab (Catumaxomab, Catumaxomab (Removab))

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast); Malignant Ascites · EpCam Positive Tumor (e.g.Ovarian, Gastr

#EpCamPositiveTumoregOvarianGastr#Antibody#Phase3#monoclonal-antibody#EpCamPositiveTumoregOvarian+3
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#monoclonal-antibody#GastricCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#monoclonal-antibody#GastricCancer+1
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →